The solid-state laser advantage

Article

Clinical outcomes of laser epithelial keratomileusis using a 213 nm wavelength solid-state laser

The 213 nm wavelength generated by solid state platforms (e.g., Pulzar Z1, CustomVis, Perth, Australia) demonstrates superior transmissibility through water compared to 193 nm, so is less sensitive to levels of corneal hydration, and may reduce the variability in refractive outcomes linked with corneal hydration; corneas that become dehydrated during excimer laser treatment are often overcorrected, while superhydration is linked with undercorrection.3 Furthermore, the absence of dangerous gas eliminates sudden noise, and patient anxiety, as laser operation commences, while maintenance costs are also substantially reduced.

Clinical outcomes

Earlier this year, we reported outcomes from a cohort of patients undergoing laser epithelial keratomileusis (LASEK) performed by the same surgeon using the CustomVis solid-state refractive laser.8 The CustomVis system generates a 213 nm wavelength by transmission of a 1064 nm Nd:YAG laser beam through three non-linear crystals. The 0.6 mm diameter quasi-Gaussian-shaped flying spot has a 300 Hz pulse repetition rate, and the system employs three methods of eye tracking technology: a limbus-based eye tracker with a closed-loop response of 1-kHz, a video eye tracker to facilitate a higher level of accuracy and a video gaze tracker, confirming patient fixation.

The cohort included 245 eyes of 134 patients with a mean age of 41.0 ± 12.2 years. Patients had a broad range of preoperative refractive errors, with sphere values ranging from –9.50 to +6.50 D (mean –1.59 ± 3.22 D) and astigmatism between 0 and –5.50 D (mean –0.98 ± 1.17 D). Postoperative follow-up visits were scheduled at 2 and 6 months.

LASEK surgery performed on this substantial cohort was shown to be effective, safe and stable over the follow-up period. Over 95% of eyes maintained the same best corrected distance visual acuity (CDVA) postoperatively, or gained a line, and the mean postoperative spherical equivalent refractive error (SE) was stable between the 2 month (–0.01 ± 0.57 D) and 6 month (–0.01 ± 0.55 D) visits. Treatment was accurate for both myopes and hyperopes, with mean SEs at 6 months of +0.02 ± 0.27 D and 0.21 ± 0.66 D, respectively.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.